Life-cycle management strategy

Utilize the following case study to evaluate and communicate your thinking on developing a compliant life-cycle management strategy:

Imagine that you, as a regulatory science expert, go camping in a remote area of the world, and find an isolated tribe of people that has not yet communicated with the rest of the world. You discover that this tribe uses several types of “magic dust” to treat a wide variety of human ailments,eachwithvaryingsafetyprofilesanddegreesofefficacy. For example, the tribe uses “magic dust #1” to treat headaches, nausea, fever and mild systemic pain, “magic dust #2” to treat cuts and bruises, and “magic dust #3” to treat insect bites. In fact, you observe that the tribe has isolated or developed at least 12 different kinds of “magic dust” and your observations suggest that the “magic dust” category as a whole seems to have a novel mechanism of action. You ask the tribe if you can have samples of each magic dust type to bring back home with you for analysis and they agree. When you get home, you give these samples to the medical research community, which discovers that indeed, these “magic dusts” might possibly be used effectively in the US to treat the conditions for which they are utilized by the tribe, and that their pharmacodynamic mechanism of action is, indeed, unique.

As a regulatory expert, you are charged with developing a product development plan to support an NDA submission to the US Food and Drug Administration (FDA) for each magic dust type. You are also responsible for developing a post-market approval plan to ensure ongoing maintenance of regulatory compliance after receipt of an NDA approval. Your plan should address the following “magic dust” associated questions and/or issues:

1) What pre-clinical requirements should be summarized in the clinical development plan?

2) How can the indications for use for each “magic dust” be isolated and refined? Why is it important to do this?

3) How can the risk vs. benefit profile associated with utilization of the “magic dust” for clinical purposes be established?

4) Should a randomized controlled trial design be utilized to conduct clinical research to support an NDA submission for the “magic dusts” or should an adaptive platform design be utilized instead?

5) Are there intellectual property issues that should be addressed?

6) How would you go about addressing pricing and reimbursement considerations?

Sample Solution